Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-04-2014 | Brief Report

Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder

Auteurs: Craig A. Erickson, Logan K. Wink, Maureen C. Early, Elizabeth Stiegelmeyer, Lauren Mathieu-Frasier, Vanessa Patrick, Christopher J. McDougle

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2014

Abstract

Rationale

An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD).

Objectives

We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD.

Materials and methods

We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder.

Results

Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale.

Conclusion

Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit.

vorige artikel Brief Report: Atypical Expression of Distress During the Separation Phase of the Strange Situation Procedure in Infant Siblings at High Risk for ASD

volgende artikel Two Proposed Early Biomarker Tests of ASD: More Harm Than Good

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain and Behavior, 4(6), 393–398. doi: 10.1111/j.1601-183X.2005.00135.x. CrossRef

Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370–377. doi: 10.1016/j.tins.2004.04.009. PubMedCrossRef

Blednov, Y. A., & Adron Harris, R. (2008). Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions. International Journal of Neuropsychopharmacology, 11(6), 775–793. doi: 10.1017/S1461145708008584. PubMedCentralPubMedCrossRef

ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 25 October 2012.

Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433. PubMedCrossRef

D’Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., et al. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research, 1121(1), 238–245. doi: 10.1016/j.brainres.2006.08.115. PubMedCrossRef

D’Hulst, C., & Kooy, R. F. (2007). The GABAA receptor: A novel target for treatment of fragile X? Trends in Neurosciences, 30(8), 425–431. doi: 10.1016/j.tins.2007.06.003. PubMedCrossRef

Erickson, C. A., Early, M., Stigler, K. A., Wink, L. K., Mullett, J. E., & McDougle, C. J. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. [Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Child and Adolescent Psychopharmacology, 21(6), 565–569. doi: 10.1089/cap.2011.0034. PubMedCentralPubMedCrossRef

Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010). Brief report: Acamprosate in fragile X syndrome. [Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Autism and Developmental Disorders, 40(11), 1412–1416. doi: 10.1007/s10803-010-0988-9. PubMedCrossRef

Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., et al. (2013). Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology (Berl),. doi: 10.1007/s00213-013-3022-z.

Gupta, T., Syed, Y. M., Revis, A. A., Miller, S. A., Martinez, M., Cohn, K. A., et al. (2008). Acute effects of acamprosate and MPEP on ethanol drinking-in-the-dark in male C57BL/6 J mice. Alcoholism: Clinical and Experimental Research, 32(11), 1992–1998. doi: 10.1111/j.1530-0277.2008.00787.x.

Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH.

Harris, B. R., Prendergast, M. A., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., et al. (2002). Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism: Clinical and Experimental Research, 26(12), 1779–1793. doi: 10.1097/01.ALC.0000042011.99580.98. CrossRef

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. doi: 10.1001/archgenpsychiatry.2009.30. PubMedCrossRef

Kotlinska, J., & Bochenski, M. (2008). The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. European Journal of Pharmacology, 598(1–3), 57–63. doi: 10.1016/j.ejphar.2008.09.026. PubMedCrossRef

Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., et al. (2011). CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. [Research Support, Non-U.S. Gov’t]. Journal of Pharmacology and Experimental Therapeutics, 339(2), 474–486. doi: 10.1124/jpet.111.185660. PubMedCrossRef

Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685. PubMedCrossRef

Mann, K., Kiefer, F., Spanagel, R., & Littleton, J. (2008). Acamprosate: Recent findings and future research directions. Alcoholism: Clinical and Experimental Research, 32(7), 1105–1110. doi: 10.1111/j.1530-0277.2008.00690.x. CrossRef

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. doi: 10.1097/CHI.0b013e3181b76658. PubMedCrossRef

Mayer, S., Harris, B., Gibson, D. A., Blanchard, J., Prendergast, M. A., Holley, R. C., et al. (2002). Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcoholism: Clinical and Experimental Research, 26(5), 655–662. CrossRef

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321. PubMedCrossRef

McDougle, C. J., Erickson, C. A., Stigler, K. A., & Posey, D. J. (2005). Neurochemistry in the pathophysiology of autism. Journal of Clinical Psychiatry, 66(Suppl 10), 9–18. PubMed

Naassila, M., Hammoumi, S., Legrand, E., Durbin, P., & Daoust, M. (1998). Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcoholism: Clinical and Experimental Research, 22(4), 802–809. CrossRef

Pierrefiche, O., Daoust, M., & Naassila, M. (2004). Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology, 47(1), 35–45. doi: 10.1016/j.neuropharm.2004.03.004. PubMedCrossRef

Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787–801, viii-ix. doi: 10.1016/j.chc.2008.06.010.

Reilly, M. T., Lobo, I. A., McCracken, L. M., Borghese, C. M., Gong, D., Horishita, T., et al. (2008). Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcoholism: Clinical and Experimental Research, 32(2), 188–196. doi: 10.1111/j.1530-0277.2007.00569.x. CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. doi: 10.1001/archpsyc.62.11.1266. CrossRef

Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., et al. (2013). Brief report: Social disability in autism spectrum disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders, 43(3), 739–746. doi: 10.1007/s10803-012-1689-3. PubMedCrossRef

Scahill, L., McDougle, C. J., Williams, S. K., Dimitropoulos, A., Aman, M. G., McCracken, J. T., et al. (2006). Children’s Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45(9), 1114–1123. PubMedCrossRef

Silverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010). Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. [Research Support, N.I.H., Intramural]. Neuropsychopharmacology, 35(4), 976–989. doi: 10.1038/npp.2009.201. PubMedCentralPubMedCrossRef

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005). Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. [Research Support, Non-U.S. Gov’t]. Neuropharmacology, 49(7), 1053–1066. doi: 10.1016/j.neuropharm.2005.06.004. PubMedCrossRef

Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature, 477(7363), 171–178. doi: 10.1038/nature10360. PubMedCrossRef

Zhang, S., Faries, D. E., Vowles, M., & Michelson, D. (2005). ADHD rating scale IV: Psychometric properties from a multinational study as a clinician-administered instrument. International Journal of Methods in Psychiatric Research, 14(4), 186–201. PubMedCrossRef

Titel: Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder
Auteurs: Craig A. Erickson
Logan K. Wink
Maureen C. Early
Elizabeth Stiegelmeyer
Lauren Mathieu-Frasier
Vanessa Patrick
Christopher J. McDougle
Publicatiedatum: 01-04-2014
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 4/2014
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-013-1943-3

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Rationale

Objectives

Materials and methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2014

Parents’ and Child Health Professionals’ Attitudes Towards Dietary Interventions for Children with Autism Spectrum Disorders

Use of a Peer Support Intervention for Promoting Academic Engagement of Students with Autism in General Education Settings

National Survey of Sensory Features in Children with ASD: Factor Structure of the Sensory Experience Questionnaire (3.0)

Two Proposed Early Biomarker Tests of ASD: More Harm Than Good

Brief Report: An Evaluation of TAGteach Components to Decrease Toe-Walking in a 4-Year-Old Child with Autism

“In the Driver’s Seat”: Parent Perceptions of Choice in a Participant-Directed Medicaid Waiver Program for Young Children with Autism